Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph Young sold 3,117 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $130,851.66. Following the transaction, the senior vice president owned 64,722 shares in the company, valued at approximately $2,717,029.56. This trade represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vera Therapeutics Stock Down 1.6%

Vera Therapeutics stock traded down $0.69 during midday trading on Wednesday, reaching $41.68. The company’s stock had a trading volume of 776,869 shares, compared to its average volume of 897,432. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The stock has a market capitalization of $2.92 billion, a P/E ratio of -10.45 and a beta of 1.16. The stock’s 50-day simple moving average is $46.63 and its 200-day simple moving average is $35.30. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VERA. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. The Goldman Sachs Group lifted their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Evercore boosted their price objective on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, Wedbush upped their target price on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.18.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Capricorn Fund Managers Ltd purchased a new position in shares of Vera Therapeutics during the 3rd quarter valued at about $13,097,000. Swedbank AB purchased a new position in Vera Therapeutics during the third quarter valued at approximately $1,453,000. Squarepoint Ops LLC lifted its holdings in Vera Therapeutics by 232.0% in the second quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after acquiring an additional 40,196 shares during the period. Bollard Group LLC purchased a new stake in Vera Therapeutics in the 2nd quarter worth approximately $1,509,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Vera Therapeutics during the 3rd quarter worth approximately $911,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.